YAFI Online Programming // Disease State Management and Drug Therapy
Special Considerations for Special Conditions
The Community Pharmacist's Guide to Specialty Medications
After participating in this activity pharmacists will be able to:
- Discuss the rapid growth of specialty pharmacy and the products most likely to be included in this category and provided by specialty-at-retail
- Identify recent changes in oncology/neutropenia, rheumatologic conditions, and dermatology products provided in specialty-at-retail settings
- Distinguish each FDA-approved product by condition it addresses
- Maximize the community pharmacist's role in specialtyat-retail product provision and counseling patients
After participating in this activity pharmacy technicians will be able to:
- Discuss the basic facts about specialty pharmacy and specialty-at-retail
- Acquire reputable sources of information for patients who engage in specialty-at-retail programs
- Distinguish between specialty products for oncology/neutropenia, rheumatologic conditions, and dermatology
- Infer when to refer patients who use specialty-at-retail programs to the pharmacist for recommendations or referral
Release Date: July 15, 2019
Expiration Date: July 15, 2021
19YC46-TKX48 Pharmacy Technician
2.0 hours of CE
Specialty medications are used to treat complex, chronic, or rare conditions, such as Crohn's disease, cystic fibrosis, growth hormone disorders, hepatitis C, HIV/AIDS, multiple sclerosis, oncology, and rheumatoid arthritis. They often require special storage and administration, increasing the need for support programs and patient education services. Specialty-at-retail programs provide the option for patients to pick up their specialty drugs at a local retail pharmacy. This provides an additional opportunity for pharmacist counseling before the medication reaches the patient. Oncolytics, medications to treat neutropenia, and drugs to treat rheumatologic and dermatologic conditions are among the most common dispensed via specialty-at-retail programs. Pharmacy teams are positioned to recognize patients who would benefit from additional counseling and teaching. Many specialty medications require specific storage and handling, and may have complicated administration techniques. Damaged medication due to improper storage and improper administration can lead to treatment failure. Pharmacists and pharmacy technicians should be able to assist patients with specialty medications and be aware of reputable resources to consult when they are unfamiliar with a specialty medication or condition. With proper education and training, pharmacy teams will be prepared and comfortable with counseling for medications dispensed via specialty-at-retail programs.
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission
Grant funding: Funded by an educational grant from Celgene
Initial Release Date: July 15, 2019
Expiration Date: July 15, 2021
To obtain CPE credit, visit the UConn Online CE Center
Use your NABP E-profile ID and the session code 19YC46-FXW93 for pharmacists or 19YC46-TKX48 for pharmacy technicians to access the online quiz and evaluation.
First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.
For questions concerning the online CPE activities, email firstname.lastname@example.org
Kelsey Giara, Pharm.D. is a community pharmacist and freelance medical writer based in New Hampshire.
Dr. Giara has no actual or potential conflicts of interest associated with this article.
Disclosure of Discussions of Off-label and Investigational Drug Use
This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Specialty medications—given by injection or orally—are used to treat complex, chronic, or rare conditions. They often require special storage and administration, increasing the need for support programs and patient education services. Specialty drugs are loosely defined by two main factors: cost and complexity. The Centers for Medicare and Medicaid Services (CMS) categorizes a specialty drug as one with a minimum cost of $600 per month under the Part D drug benefit.1,2 Other organizations may establish higher cost thresholds, often exceeding $10,000 monthly or $100,000 annually. Specialty drugs encompass many factors, including2,3:
- Treatment of complex, chronic, and/or rare conditions
- Availability through restricted or limited distribution
- Special storage, administration, and/or handling requirements
- Risk Evaluation Mitigation Strategy (REMS) program necessity
- Ongoing need for safety and efficacy monitoring
Due to specialty drugs’ sensitive nature and price points that are higher than traditional medications', self-identified “specialty pharmacies” are becoming increasingly more common entities. Specialty pharmacies’ standard care surpasses the services offered at a typical retail pharmacy. These additional services may include2:
- 24-hour access to a pharmacist
- Adherence management
- Dispensing of specialty medications and shipping coordination
- Financial assistance and enrollment in patient assistance programs
- Patient education and adverse effect counseling
- Monitoring for safety and efficacy
- Prior authorization assistance
- Proactive patient outreach for timely refill and renewal
Full List of References
1. Medicare Prescription Drug Benefit Manual: Chapter 6 – Part D Drugs and Formulary Requirements. Available at: https://www.cms.gov/Medicare/Prescription-DrugCoverage/PrescriptionDrugCovContra/Downloads/Part-D-BenefitsManual-Chapter-6.pdf. Accessed April 1, 2019.
2. Hagerman J, Freed S, Rice G. Specialty Pharmacy: A Unique and Growing Industry. American Pharmacists Association. Published July 2013. http://www.pharmacist.com/specialty-pharmacy-unique-andgrowing-industry. Accessed January 14, 2019.
3. National Association of Specialty Pharmacy. NASP Definitions of Specialty Pharmacy and Specialty Medications. Published February 24, 2016. http://naspnet.org/wp-content/uploads/2017/02/NASP-Defintions-final-2.16.pdf. Accessed January 14, 2019.
4. Drug Channels: Expert Insights on Pharmaceutical Economic and the Drug Distribution System. Exclusive Update: The State of Specialty Pharmacy Accreditation in 2017. Published April 13, 2017. https://www.drugchannels.net/2017/04/exclusive-update-state-ofspecialty.html. Accessed January 14, 2019.
5. Drug Channels: Expert Insights on Pharmaceutical Economic and the Drug Distribution System. The Specialty Pharmacy Accreditation Boom Continues. Published March 10, 2016. https://www.drugchannels.net/2016/03/the-specialty-pharmacyaccreditation.html. Accessed January 14, 2019.
6. U.S. Food & Drug Administration. Novel Drug Approvals for 2017. Updated February 2018. https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040.htm. Accessed January 14, 2019.
7. Pharmaceutical Executive. 2016 Pharm Science Strategic Outlook – – An Industry in Flux: 2015-–2016 Market Trends. Published February 2016. http://files.pharmtech.com/alfresco_images/pharma/2016/02/25/3d9096e7-6975-457b-be99-2867668f3844/PharmaScienceStrategicOutlook2016.pdf. Accessed January 14, 2019.
8. United Health Center for Health Reform & Modernization. The Growth of Specialty Pharmacy: Current Trends and Future Opportunities. Published April 2014. http://www.unitedhealthgroup.com/~/media/UHG/PDF/2014/UNH‐The-Growth-Of-Specialty-Pharmacy.ashx. Accessed January 14, 2019.
9. CVS Specialty Pharmacy Distribution Drug List: Effective April 2019. Available at: https://www.cvsspecialty.com/educationcenter/downloads/SpecialtyDrugs.pdf. Accessed May 1, 2019.
10. AllianceRx (Walgreens specialty) pharmacy list of specialty medications: Effective March 2019. Available at: https://www.messa.org/pdf/walgreens_specialty_meds.pdf. Accessed May 1, 2019.
11. Advisory Board. Specialty pharmacy, explained. Published February 22, 2018. https://www.advisory.com/research/care-transformationcenter/care-transformation-center-blog/2018/03/specialty-pharmacy. Accessed May 1, 2019.
12. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999 2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, June 2018.
13. Lash S. Learning to love your specialty pharmacy: perspective on a new business relationship. Biotechnol Healthc. 2007;4(5):45-48.
14. Specialty pharmacy improves cancer outcomes. Express Scripts web site. http://lab.express-scripts.com/insights/specialtymedications/specialty-pharmacy-improves-cancer-outcomes. Published December 19, 2013. Accessed January 16, 2019.
15. “What is Non-Small Cell Lung Cancer?” American Cancer Society. Revised May 16, 2016. https://www.cancer.org/cancer/non-small-celllung cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed April 1, 2019.
16. American Society of Hematology. Blood Cancers. https://www.hematology.org/Patients/Cancers/. Accessed May, 02,2019.
17. Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities. Onco Targets Ther. 2018 Sep 25;11:6227-6237
18. Hartmann JT, Haap M, Hopp H, Lipp H. Tyrosine Kinase Inhibitors – AReview on Pharmacology, Metabolism, and Side Effects. Curr Drug Metab. 2009 Jun;10(5):470-81.
19. Nerlynx (neratinib) package insert. Los Angeles, CA: Puma Biotechnology, Inc.; 2017.
20. Alecensa (alectinib) package insert. South San Francisco, CA: Genentech USA, Inc.; 2015.
21. Inlyta (axitinib) package insert. New York, NY: Pfizer Labs; 2012.
22. Bosulif (bosutinib) package insert. New York, NY: Pfizer Labs; 2012.
23. Alunbrig (brigatinib) package insert. Cambridge, MA: Ariad Pharmaceuticals, Inc.; 2017.
24. Cabometyx (cabozantinib) package insert. South San Francisco, CA: Exelixis, Inc.; 2012.
25. Zykadia (ceritinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2014.
26. Xalkori (crizotinib) package insert. New York, NY: Pfizer Labs; 2011.
27. Vizimpro (dacomitinib) package insert. New York, NY: Pfizer Labs;2018.
28. Sprycel (dasatinib) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006.
29. Tarceva (erlotinib) package insert. Northbrook, IL: OSI Pharmaceuticals, LLC; 2016.
30. Iressa (gefitinib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
31. Gleevec (imatinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2017.
32. Tykerb (lapatinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2018.
33. Lorbrena (lorlatinib) package insert. New York, NY: Pfizer Labs; 2018.
34. Tasigna (nilotinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2018.
35. Tagrisso (osimertinib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
36. Jakafi (ruxolitinib) package insert. Wilmington, DE: Incyte Corporation; 2016.
37. Sutent (sunitinib) package insert. New York, NY: Pfizer Labs; 2017.
38. Mekinist (trametinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2018.
39. Pharmacy Times. Get to Know an Enzyme: CYP3A4. Published September 1, 2008. https://www.pharmacytimes.com/publications/issue/2008/2008-
09/2008-09-8687. Accessed May, 1 2019.
40. Sherbet GV. Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. Anticancer Res. 2015 Nov;35(11):5767-72.
41. Thalomid (thalidomide) package insert. Summit, NJ: Celgene Corporation; 2017.
42. Revlimid (lenalidomide) package insert. Summit, NJ: Celgene Corporation; 2019.
43. Pomalyst (pomalidomide) package insert. Summit, NJ: Celgene Corporation; 2018.
44. Dana Farber Cancer Institute. Oral Chemotherapy. https://www.dana-farber.org/chemotherapy/oral-chemotherapy/. Accessed May 1, 2019.
45. Dana Farber Cancer Institute. Oral chemotherapy fact sheet. https://www.dana-farber.org/health-library/articles/oralchemotherapy-fact-sheet/. Accessed May 1, 2019.
46. Beleodaq (belinostat) package insert. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2014.
47. Dacogen (decitabine) package insert. Dublin, CA: Astex Pharmaceuticals, Inc.; 2018.
48. Evomela (melphalan) package insert. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2016.
49. Fusilev (levoleucovorin) package insert. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2011.
50. Halaven (eribulin mesylate) package insert. Woodcliff Lake, NJ: Eisai, Inc.; 2016.
51. Istodax (romidepsin) package insert. Summit, NJ: Celgene Corporation; 2014.
52. Jevtana (cabazitaxel) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2010.
53. Lupron Depot (leuprolide acetate) package insert. North Chicago, IL: AbbVie Inc.; 2019.
54. Sylatron (peginterferon alfa-2b) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2015.
55. Treanda (bendamustine) package insert. Frazer, PA: Cephalon, Inc.; 2008.
56. Trelstar (triptorelin) package insert. Parsippany, NJ: Actavis Pharma, Inc.; 2014.
57. Velcade (bortezomib) package insert. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2008.
58. Vidaza (azacitidine) package insert. Summit, NJ: Celgene Corporation; 2018.
59. Zoladex (goserelin) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009.
60. Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. Journal of
Oncology Practice 2017;13(6):e552–e561.
61. Cancer.Net: Doctor-Approved Patient Information from ASCO (American Society of Clinical Oncology). Neutropenia. Published February 2018. https://www.cancer.net/coping-with-cancer/physicalemotional-and-social-effects-cancer/managing-physical-sideeffects/neutropenia. Accessed May 1, 2019.
62. Neopogen (filgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2016.
63. Neulasta (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2016.
64. Leukine (sargramostim) package insert. Bridgewater, NJ: Sanofi Aventis U.S. LLC; 2018.
65. American College of Rheumatology. Prevalence Statistics. https://www.rheumatology.org/LearningCenter/Statistics/Prevalence-Statistics. Accessed May 1, 2019.
66. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012 Dec;18(13 Suppl):S295-302.
67. Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). Reviewed March 5, 2019. https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html. Accessed May 1, 2019.
68. National Rheumatoid Arthritis Society (UK). Anti-TNFa Treatment in Rheumatoid Arthritis. Reviewed January 14, 2019. https://www.nras.org.uk/anti-tnfa-treatment-in-rheumatoid-arthritis. Accessed May 1, 2019.
69. Humira (adalimumab) package insert. North Chicago, IL: AbbVie Inc.; 2019.
70. Cimzia (certolizumab pegol) package insert. Smyrna, GA: UCB, Inc.; 2016.
71. Enbrel (etanercept) package insert. Thousand Oaks, CA: Amgen Inc.; 2017.
72. Simponi (golimumab) package insert. Horsham, PA: Janssen Biotech, Inc.; 2011.
73. Remicade (infliximab) package insert. Horsham, PA: Janssen Biotech, Inc.; 2013.
74. Orencia (abatacept) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
75. Otezla (apremilast) package insert. Summit, NJ: Celgene Corporation; 2017.
76. Olumiant (baricitinib) package insert. Indianapolis, IN: Eli Lilly and Company; 2018.
77. Siliq (brodalumab) package insert. Bridgewater, NJ: Valeant Pharmaceuticals LLC; 2017.
78. Tremfya (guselkumab) package insert. Horsham, PA: Janssen Biotech, Inc.; 2017.
79. Taltz (ixekizumab) package insert. Indianapolis, IN: Eli Lilly and Company; 2016.
80. Otrexup (methotrexate) package insert. Ewing, NJ: Antares Pharma, Inc.; 2018.
81. Rituxan (rituximab) package insert. South San Francisco, CA: Genentech USA, Inc.; 2019.
82. Kevzara (sarilumab) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2017.
83. Cosentyx (secukinumab) package insert. East Hanover, NJ: Novartis Pharmaceuticals Coroporation; 2016.
84. Ilumya (tildrakizumab-asmn) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2018.
85. Actemra (tocilizumab) package insert. South San Francisco, CA: Genentech USA, Inc.; 2013.
86. Xeljanz (tofacitinib) package insert. New York, NY: Pfizer Labs; 2018.
87. Stelara (ustekinumab) package insert. Horsham, PA: Janssen Biotech, Inc.; 2012.
88. Abbvie, Inc. "HUMIRA CITRATE FREE ADULT SELF-INJECTION PEN" TRANSCRIPT. https://www.humira.com/humiracomplete/ transcript_adultPen. Accessed May 15, 2019.
89. Cimzia prefilled syringe – step-by-step instructions for use. Available at: https://www.cimzia.com/sites/default/files/inlinefiles/IFU_Brochure.pdf
90. Enbrel dosing and administration. Available at: https://www.enbrel.com/hcp/dosing-and-administration
91. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec 28;17(1):78.
92. National Psoriasis Foundation. About Psoriasis/Statistics. Reviewed October 23, 2018. https://www.psoriasis.org/about-psoriasis. Accessed May 15, 2019.
93. DiPiro, Joseph T. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill Medical, 2008.
94. Rasuvo (methotrexate) package insert. Chicago, IL: Medac Pharma Inc.; 2018.
95. Maryland Poison Center: University of Maryland School of Pharmacy. Tox Tidbits: Methotrexate Toxicity. Published January 2009. https://mdpoison.com/media/SOP/mdpoisoncom/ToxTidbits/2009/January%202009%20toxtidbits.pdf. Accessed May 1, 2019.